{
    "clinical_study": {
        "@rank": "147908", 
        "acronym": "ADO pMDI", 
        "arm_group": [
            {
                "arm_group_label": "CHF 1535 100/6 pMDI (Foster\u00ae) TEST 1", 
                "arm_group_type": "Active Comparator", 
                "description": "Adolescents CHF 1535 100/6, 4 puffs (total dose: BDP 400 \u00b5g/FF 24 \u00b5g) pMDI"
            }, 
            {
                "arm_group_label": "CHF 1535 100/6 pMDI (Foster\u00ae) AeroChamber Plus\u2122  (TEST 2).", 
                "arm_group_type": "Active Comparator", 
                "description": "CHF 1535 100/6 pMDI (Foster\u00ae) using AeroChamber Plus\u2122 spacer device in adolescents (TEST 2)"
            }, 
            {
                "arm_group_label": "(Qvar\u00ae: BDP 400 \u00b5g)+(Atimos\u00ae: formoterol 24 \u00b5g)", 
                "arm_group_type": "Active Comparator", 
                "description": "BDP 100 \u00b5g pMDI, 4 puffs (Qvar\u00ae, total dose: BDP 400 \u00b5g) + formoterol fumarate 6 \u00b5g pMDI, 4 puffs (Atimos\u00ae, total dose: formoterol 24 \u00b5g)"
            }, 
            {
                "arm_group_label": "CHF 1535 100/6, 4 puffs (total dose: BDP 400 \u00b5g/FF 24 \u00b5g) pMDI", 
                "arm_group_type": "Active Comparator", 
                "description": "Adults CHF 1535 100/6, 4 puffs (total dose: BDP 400 \u00b5g/FF 24 \u00b5g) pMDI"
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical pharmacology want to investigate the systemic availability of BDP/B17MP\n      (active metabolite of BDP) and formoterol after single oral inhalation of CHF 1535 100/6\n      pMDI with and without spacer device (AeroChamber Plus\u2122) and in comparison to a free\n      combination of BDP pMDI plus formoterol pMDI licensed products;  this will be additionally\n      compared to the systemic exposure in adults without the spacer device."
        }, 
        "brief_title": "Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "The proposed clinical pharmacology study is aimed to investigate the systemic availability\n      of BDP/B17MP (active metabolite of BDP) and formoterol after single oral inhalation of CHF\n      1535 100/6 pMDI (to reach a total dose of BDP 400 \u00b5g and formoterol 24 \u00b5g) with and without\n      spacer device (AeroChamber Plus\u2122) and in comparison to a free combination of BDP pMDI plus\n      formoterol pMDI licensed products (to reach the same total dose of BDP and formoterol) in\n      adolescent asthmatic patients. The systemic exposure to BDP/B17MP and formoterol after\n      inhalation of CHF 1535 pMDI in adolescents will be additionally compared to the systemic\n      exposure in adults without the spacer device.\n\n      The chosen doses correspond to the maximum daily dose of the two components administered as\n      fixed combination."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "- Inclusion criteria\n\n        Patients will be enrolled if they meet all of the following criteria:\n\n          1. Male and female adolescents, aged \u2265 12 and < 18 years at the time of Screening Visit\n             or male and female adults, aged \u2265 18 and \u2264 65 years at the time of Screening Visit.\n\n          2. Written informed consent obtained by the patient in case of adult patients and by\n             parents/legal representative and by the minor (according to local regulation).\n\n          3. A diagnosis of asthma as defined in the GINA guidelines (updated 2010) 6 months\n             before the screening visit.\n\n          4. Male/female adolescent and adult patients with asthma stable enough, according to\n             GINA guidelines (updated 2010) and based on the Investigator's opinion, to allow a\n             wash out period from inhaled BDP of 2 days before each single day study treatments\n             and any ICS other than BDP of 1 day before each single day study treatments.\n\n          5. Male/female adolescents and adults asthmatic patients already treated with ICS or\n             ICS/long-acting inhaled \u03b22-agonists or using short-acting inhaled \u03b22-agonists as\n             reliever to control asthma symptoms.\n\n          6. Adolescents and adults with a forced expiratory volume in one second (FEV1) > 70% of\n             predicted values (% pred) after withholding short acting \u03b22-agonist treatment for a\n             minimum of 6 h prior to screening or 24 hours in case of long acting \u03b22-agonist.\n\n          7. Non- or ex-smokers who smoked less than 5 pack-years (e.g. < 20 cigarettes per day\n             for 5 years) and stopped smoking for at least 1 year.\n\n          8. A cooperative attitude and ability to be trained about the proper use of pMDI with\n             and without a spacer device and compliant to study procedures.\n\n          9. Body mass index (BMI) \u226518.5 and \u2264 32 kg/m2\n\n               -  Exclusion criteria\n\n        Patients will not be enrolled if one or more of the following criteria are present:\n\n          1. Pregnant or breast-feeding female patients. Sexually active female not using\n             efficient contraception throughout the entire study period (e.g.\n             oestro-progestatives, condoms, intrauterine devices). A urinary pregnancy test will\n             be performed at screening and treatment visits (mandatory in the adult population and\n             at discretion of the investigator in the adolescent population) in women of\n             childbearing potential;\n\n          2. Having received an investigational drug within 2 months before the screening visit\n             (Visit 1).\n\n          3. Diagnosis of COPD, in the adult patients, as defined by the current GOLD guidelines\n             (updated 2010).\n\n          4. Known hypersensitivity to the active treatments.\n\n          5. Inability to perform the required breathing technique and blood sampling.\n\n          6. Hospitalization due to exacerbation of asthma within 1 month prior to the screening\n             visit.\n\n          7. Lower respiratory tract infection within 1 month prior to screening visit.\n\n          8. Obesity, i.e. > 97% weight percentile by local standards.\n\n          9. Significant medical history of and/or treatments for cardiac, renal, neurological,\n             hepatic, endocrine diseases, that may interfere with patient's safety, compliance, or\n             study evaluations, according to the Investigator's opinion;\n\n         10. History of drug addiction or excessive use of alcohol (weekly intake in excess of 28\n             units alcohol; one unit being a glass of beer, wine or a measure of spirits), or\n             excessive consumption of xanthine containing substances (daily intake in excess of 5\n             cups of coffee, tea, cola, etc) or psychological or other emotional problems likely\n             to invalidate informed consent, or limit the ability of the subject to comply with\n             the protocol requirements;\n\n         11. Treatment with a xanthine derivative (e.g. theophylline) formulations in the 4 weeks\n             prior to screening;\n\n         12. Blood donation (450 mL or more) (for the adult population) or significant blood loss\n             in the 12 weeks before the screening visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01803087", 
            "org_study_id": "CCD-1104-PR-0062"
        }, 
        "intervention": [
            {
                "arm_group_label": "CHF 1535 100/6 pMDI (Foster\u00ae) TEST 1", 
                "intervention_name": "Test treatments CHF 1535 100/6 pMDI (Foster\u00ae) TEST1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CHF 1535 100/6 pMDI (Foster\u00ae) AeroChamber Plus\u2122  (TEST 2).", 
                "intervention_name": "CHF 1535 100/6 pMDI (Foster\u00ae) using AeroChamber Plus\u2122  (TEST 2).", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "(Qvar\u00ae: BDP 400 \u00b5g)+(Atimos\u00ae: formoterol 24 \u00b5g)", 
                "intervention_name": "BDP pMDI 100 \u00b5g (Qvar\u00ae) plus formoterol fumarate pMDI 6 \u00b5g (Atimos\u00ae) (REF)", 
                "intervention_type": "Drug", 
                "other_name": "Free combination of BDP pMDI 100 \u00b5g (Qvar\u00ae) plus formoterol fumarate pMDI 6 \u00b5g (Atimos\u00ae) in adolescents (REF)"
            }, 
            {
                "arm_group_label": "CHF 1535 100/6, 4 puffs (total dose: BDP 400 \u00b5g/FF 24 \u00b5g) pMDI", 
                "intervention_name": "CHF 1535 100/6 pMDI  (Foster\u00ae) (CTR)", 
                "intervention_type": "Drug", 
                "other_name": "CHF 1535 100/6 pMDI  (Foster\u00ae) in adults (CTR)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Beclomethasone", 
                "Formoterol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "adolescents", 
            "adults"
        ], 
        "lastchanged_date": "March 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lodz", 
                    "country": "Poland", 
                    "zip": "90153"
                }, 
                "name": "Uniwersytecki Szpital Kliniczny nr 1"
            }
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "4", 
        "official_title": "A SINGLE-DOSE, OPEN LABEL, RANDOMIZED, 3-WAY CROSSOVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 100/6 pMDI (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100 \u00b5g PLUS FORMOTEROL FUMARATE 6 \u00b5g) WITH OR WITHOUT SPACER DEVICE VERSUS THE FREE COMBINATION OF LICENSED BECLOMETHASONE pMDI AND FORMOTEROL pMDI IN ASTHMATIC ADOLESCENT PATIENTS AND ONE OPEN ARM FOR ADULT PATIENTS AS CONTROL GROUP TREATED WITH CHF 1535 100/6 pMDI.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Poland: National Institute of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "In adolescents, the  systemic exposure of B17MP  as  AUC0-t, after inhalation of CHF 1535 100/6 pMDI with and without spacer device (AeroChamber Plus\u2122) vs already licensed free combination of BDP pMDI and formoterol pMDI without spacer.", 
            "measure": "AUC0-t of B17MP CHF 1535 100/6 pMDI with and without spacer vs free combination of BDP pMDI and formoterol pMDI", 
            "safety_issue": "No", 
            "time_frame": ": pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01803087"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "In adolescents,  after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.", 
                "measure": "AUC0-t, AUC0-inf, Cmax, tmax and t\u00bd for BDP and formoterol", 
                "safety_issue": "No", 
                "time_frame": ": pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation."
            }, 
            {
                "description": "In adolescents,  after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.", 
                "measure": "AUC0-0.5h, AUC0-inf, Cmax, tmax and t\u00bd for B17MP", 
                "safety_issue": "No", 
                "time_frame": ": pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation."
            }, 
            {
                "description": "In adolescents,  after inhalation of CHF 1535 100/6 pMDI with and without spacer (AeroChamber Plus\u2122)vs fre combination", 
                "measure": "plasma glucose and plasma potassium AUC0-t; Cmin; Tmin; Cmax; Tmax", 
                "safety_issue": "No", 
                "time_frame": ": pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation."
            }, 
            {
                "description": "In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs free combination", 
                "measure": "Heart rate as AUC0-8h  of CHF 1535 100/6 pMDI", 
                "safety_issue": "No", 
                "time_frame": "pre-dose (within 5 min from dosing), 5 min; 10 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation."
            }, 
            {
                "description": "In adolescents,  after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.", 
                "measure": "FEV1; time everaged FEV1 value AUC0-8h; peak FEV1", 
                "safety_issue": "No", 
                "time_frame": "pre-dose;  30 min; 1, 2, 4, 6 and 8 hr after inhalation."
            }
        ], 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}